Pharmaceutical company in the
Canton of Zurich

IMCD Switzerland AG

Since 1957 · 21–50 empl.

IMCD Switzerland AG is part of the IMCD Group, which formulates, sells and distributes speciality chemicals and ingredients. Its products serve a range of markets, including food and nutrition, beauty and personal care, and pharmaceuticals.

Galepharm AG

Since 1959 · 11–20 empl.

Galepharm AG is a pharmaceutical company and marketing authorisation holder for prescription-only niche medicines. Its products include diuretics as well as oral and injectable corticosteroids.

Schweizer Blisterzentrum AG

Since 1986 · 11–20 empl.

Schweizer Blisterzentrum AG provides industrial, patient-specific packaging of solid medicines according to medical prescriptions and on behalf of pharmacies. Medicines for each dosing time are grouped in labelled pouches, checked and prepared for delivery to the pharmacy.

Astellas Pharma AG

Since 1987 · 21–50 empl.

Astellas Pharma AG is a pharmaceutical company engaged in researching, developing, manufacturing and supplying medicines. Its portfolio includes therapies in oncology, ophthalmology, urology, immunology and women's health.

Virbac (Switzerland) AG

Since 1988 · 101–500 empl.

Virbac (Switzerland) AG offers products for the health of companion and farm animals. Its range includes food and dietary food, supplements, care products and parasite control products for dogs, cats, horses and cattle.

ALK-Abelló AG

Since 1990 · 101–500 empl.

ALK-Abelló AG is the Swiss subsidiary of ALK-Abelló and specialises in the prevention, diagnosis and treatment of allergies. Its activities include specific immunotherapy, with subcutaneous products and sublingual tablets for common respiratory allergies.

Cedem AG

Since 1991 · 21–50 empl.

Cedem AG develops and distributes targeted nutritional supplements for women’s health. Its products address needs across different life stages and areas including PMS, PCOS, fertility, pregnancy, lactation and menopause.

Almirall AG

Since 1992 · 101–500 empl.

The core activity of Almirall is the development, manufacture and marketing of pharmaceuticals, particularly in the field of dermatology and skin health. The company focuses on researching and developing innovative medical solutions for the treatment of skin diseases and other health issues.

A. Menarini GmbH

Since 1996 · 21–50 empl.

A. Menarini GmbH is the Swiss subsidiary of the Menarini Group and supplies pharmaceutical products, particularly for primary care. Its therapeutic areas include allergology, diabetology, gastroenterology, cardiovascular medicine, infectious diseases and rheumatology.

Daiichi Sankyo (Schweiz) AG

Since 1998 · 21–50 empl.

Daiichi Sankyo (Schweiz) AG distributes medicines in the fields of cardiovascular disease and oncology. It is part of a global pharmaceutical company that researches and develops new medicines.

Target BioScience AG

Since 2000 · 1–10 empl.

Target BioScience AG provides consulting and services to pharmaceutical and healthcare businesses. Its activities include medicinal product authorizations and regulatory support, marketing authorization holder services, market access, quality management, and IT compliance, data science and software engineering.

Roche Glycart AG

Since 2000 · 11–20 empl.

Roche Glycart AG operates within Roche Pharma research. Roche’s research site in Schlieren is described as the origin of the company’s glyco-engineering technology.

Lipal Biochemicals AG

Since 2000 · 1–10 empl.

Lipal Biochemicals AG is a fine chemicals producer that researches, develops and manufactures complex biochemical products, including amino acid derivatives, resins and peptides. Its offerings include biologically active peptides and custom peptide synthesis.

GE Healthcare AG

Since 2000 · 101–500 empl.

GE Healthcare AG distributes pharmaceutical products for medical imaging, including contrast media and molecular imaging agents. These products support diagnostic examinations and clinical assessment.

OrPha Swiss GmbH

Since 2003 · 11–20 empl.

The core activity of OrPha Swiss is the development, manufacture and marketing of medicines for rare diseases (Orphan Diseases) and niche areas, particularly in the fields of pulmonary hypertension, infectiology and intensive and emergency medicine.

Biotech Concepts GmbH

Since 2005 · 1–10 empl.

Biotech Concepts GmbH develops biotechnological production processes and provides consulting and project management for the biotechnology and pharmaceutical industries. Its activities include process development, technology transfer and processes for manufacturing active pharmaceutical ingredients, particularly antibiotics.

Eisai Pharma AG

Since 2005 · 11–20 empl.

Eisai Pharma AG is a research-oriented pharmaceutical company within the Eisai Group. Its Swiss branch markets and distributes medicines, with a focus on neurology and oncology.

CONARTIX GmbH

Since 2006 · 1–10 empl.

The core activity of Conartix Health AG is the development, manufacture and marketing of nature-based health products and dietary supplements, particularly based on plant-based substances and prebiotics, with the aim of promoting human health and quality of life.

Vaccentis AG

Since 2006 · 11–20 empl.

Vaccentis AG develops protein-based tumour vaccines using its AIPI platform for individualized precision immunotherapy. Its most advanced product candidate, VCC-001, is being developed for the adjuvant treatment of renal cell carcinoma, while other candidates are in research and preclinical testing for additional cancers.

Philochem AG

Since 2006 · 11–20 empl.

The core activity of Philochem is the development and research of bioactive compounds for cancer treatment, particularly in the areas of Target Discovery, Ligand Discovery and small molecule therapeutics. The company focuses on developing compounds that target the site of the disease while protecting healthy tissue. The company's products include various radiopharmaceuticals for imaging and therapy of cancer, such as 68Ga-OncoFAP, 177Lu-OncoFAP and 68Ga-OncoCAIX.

Redbiotec AG

Since 2006 · 11–20 empl.

Redbiotec AG is a biotechnology company that engineers microorganisms for research and applications in oncology and gene therapy. It also develops and produces proteins and genetic materials for the biopharmaceutical and food industries, and works on therapeutic vaccines, casein proteins and DNA products.

Takeda Pharmaceuticals International AG

Since 2007 · 51–100 empl.

Takeda Pharmaceuticals International AG is Takeda’s regional headquarters and corporate office in Switzerland.

Herb-pharma AG

Since 2008 · 1–10 empl.

Herb-pharma AG develops and manufactures cosmetics, nutritional products, medical devices and other health products. Its brands include Fytofontana, Virostop, Gyntima, Aurecon and Hemorrelax.

steinberg pharma ag

Since 2008 · 1–10 empl.

steinberg pharma ag distributes medicines, particularly complementary medicine products, medical devices, products for podology professionals and food supplements. The company also develops its own products and provides services in storage, field sales, consulting and regulatory affairs.

Virometix AG

Since 2009 · 11–20 empl.

Virometix AG is a clinical-stage biotechnology company developing synthetic vaccines against infectious diseases. Its proprietary nanoparticle platform is being used for vaccine candidates including those targeting pneumococcal disease and respiratory syncytial virus (RSV).

NORIS PHARMA AG

Since 2011 · 1–10 empl.

NORIS PHARMA AG develops and sells its own OTC products, medical devices and food supplements. It also supports partners with the development, production, registration and market launch of medicines, medical devices, food supplements and cosmetics.

MedComms Experts GmbH

Since 2012 · 11–20 empl.

MedComms Experts GmbH is part of Kinetix Health Group, which provides scientific communications for pharmaceutical and biotechnology companies. Its services include Medical Affairs strategy, medical content and digital solutions for engaging healthcare professionals.

Axanton Technology GmbH

Since 2013 · 1–10 empl.

Axanton Technology GmbH develops a technology platform for producing MEMS, a class of therapeutic biomolecules targeting cell-membrane signalling. Its development pipeline includes A-144, a drug candidate intended to affect cell degeneration.

SENTISS AG

Since 2013 · 21–50 empl.

Sentiss Pharma is a pharmaceutical company specializing in the development and manufacture of medicines, particularly in the field of ophthalmology and special products. The company's core activity includes research and development of new medicines, production of high-quality products, and provision of health solutions for customers worldwide. In contrast, Inzox is a financial services provider specializing in providing financial solutions for companies and private individuals. The company's core activity includes providing financial advisory services, managing assets, and providing financial products.

SLC Bellevue GmbH

Since 2013 · 11–20 empl.

The core activity of SLC Bellevue GmbH - LUXES COSMETICS is the development, manufacture and marketing of natural cosmetics products, particularly skin care products, under the LUXES brand.

Otsuka Pharmaceutical (Switzerland) GmbH

Since 2013 · 11–20 empl.

The core activity of Otsuka Pharmaceutical Europe Ltd. is the development, manufacture and marketing of pharmaceutical products and nutritional supplements (Nutraceuticals) to improve the health and well-being of people worldwide.

Swiss Bioscience GmbH

Since 2014 · 11–20 empl.

Swiss Bioscience GmbH develops and produces stem cell products from human adipose tissue under cGMP conditions and offers cryopreservation of SVF and hADSCs. The company conducts research and development on stem cells, extracellular vesicles and cell-based applications for regenerative medicine.

Alvotech Swiss AG

Since 2014 · 21–50 empl.

Alvotech Swiss AG develops and manufactures biosimilars, with a pipeline focused on monoclonal antibodies and other biologic medicines. The company follows a vertically integrated approach from R&D through drug product manufacturing and collaborates with commercial partners for market access.

NovaGo Therapeutics AG

Since 2015 · 11–20 empl.

NovaGo Therapeutics AG is a biotechnology company developing therapeutic antibodies to promote nerve growth and regeneration in the central nervous system. Its lead candidate, NG004, is being clinically evaluated for acute spinal cord injury, and another development programme targets diabetic retinopathy.

Dr. Andres Pharma AG

Since 2015 · 11–20 empl.

Dr. Andres Pharma AG develops and manufactures herbal medicines and medical devices, including comfrey ointments and gels for muscle and joint complaints, as well as nasal ointments and hand disinfectants. Its fresh-plant products use medicinal herbs grown organically in Switzerland.

Advanz Pharma Specialty Medicine Switzerland GmbH

Since 2015 · 1–10 empl.

Advanz Pharma Specialty Medicine Switzerland GmbH is a pharmaceutical company that commercialises specialty, hospital and rare disease medicines. Its portfolio includes biosimilars, specialty generics and originator brands, and it works with biopharma and pharmaceutical development partners.

Jantar GmbH

Since 2015 · 1–10 empl.

Jantar GmbH is a pharmaceutical research and development company focused on chronic rhinosinusitis. It is developing dicholine succinate as an active ingredient for a nasal spray and preparing for its further clinical development.

Cellerys AG

Since 2015 · 11–20 empl.

Cellerys AG develops therapies intended to restore immune tolerance in autoimmune diseases, particularly multiple sclerosis. Its CLS12311 approach uses a patient’s own red blood cells coupled with disease-related peptides to promote antigen-specific immune tolerance.